BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Börgeson E, Johnson AM, Lee YS, Till A, Syed GH, Ali-Shah ST, Guiry PJ, Dalli J, Colas RA, Serhan CN, Sharma K, Godson C. Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. Cell Metab 2015;22:125-37. [PMID: 26052006 DOI: 10.1016/j.cmet.2015.05.003] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 15.7] [Reference Citation Analysis]
Number Citing Articles
1 de Gaetano M, Butler E, Gahan K, Zanetti A, Marai M, Chen J, Cacace A, Hams E, Maingot C, Mcloughlin A, Brennan E, Leroy X, Loscher CE, Fallon P, Perretti M, Godson C, Guiry PJ. Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms). European Journal of Medicinal Chemistry 2019;162:80-108. [DOI: 10.1016/j.ejmech.2018.10.049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
2 Doyle R, Sadlier DM, Godson C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin Immunol 2018;40:36-48. [PMID: 30293857 DOI: 10.1016/j.smim.2018.09.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
3 Johnson AMF, Hou S, Li P. Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTB4 are pro-inflammatory molecules that can be targeted to restore insulin sensitivity. Bioessays 2017;39. [PMID: 28752547 DOI: 10.1002/bies.201700036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Araújo AC, Wheelock CE, Haeggström JZ. The Eicosanoids, Redox-Regulated Lipid Mediators in Immunometabolic Disorders. Antioxid Redox Signal 2018;29:275-96. [PMID: 28978222 DOI: 10.1089/ars.2017.7332] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Silva CAM, Belisle JT. Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis. Front Immunol 2018;9:134. [PMID: 29472920 DOI: 10.3389/fimmu.2018.00134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wu J, Ding DH, Li QQ, Wang XY, Sun YY, Li LJ. Lipoxin A4 Regulates Lipopolysaccharide-Induced BV2 Microglial Activation and Differentiation via the Notch Signaling Pathway. Front Cell Neurosci 2019;13:19. [PMID: 30778288 DOI: 10.3389/fncel.2019.00019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
7 Dahik VD, Frisdal E, Le Goff W. Rewiring of Lipid Metabolism in Adipose Tissue Macrophages in Obesity: Impact on Insulin Resistance and Type 2 Diabetes. Int J Mol Sci 2020;21:E5505. [PMID: 32752107 DOI: 10.3390/ijms21155505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Gao F, Lv YW, Long J, Chen JM, He JM, Ruan XZ, Zhu HB. Butyrate Improves the Metabolic Disorder and Gut Microbiome Dysbiosis in Mice Induced by a High-Fat Diet. Front Pharmacol 2019;10:1040. [PMID: 31607907 DOI: 10.3389/fphar.2019.01040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
9 Qi X, Zhang B, Zhao Y, Li R, Chang HM, Pang Y, Qiao J. Hyperhomocysteinemia Promotes Insulin Resistance and Adipose Tissue Inflammation in PCOS Mice Through Modulating M2 Macrophage Polarization via Estrogen Suppression. Endocrinology 2017;158:1181-93. [PMID: 28323956 DOI: 10.1210/en.2017-00039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
10 Jaén RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases. Front Immunol 2021;12:658840. [PMID: 33968061 DOI: 10.3389/fimmu.2021.658840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Lv Q, Gao R, Peng C, Yi J, Liu L, Yang S, Li D, Hu J, Luo T, Mei M, Song Y, Wu C, Xiao X, Li Q. Bisphenol A promotes hepatic lipid deposition involving Kupffer cells M1 polarization in male mice. J Endocrinol 2017;234:143-54. [PMID: 28500084 DOI: 10.1530/JOE-17-0028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Queck A, Fink AF, Sirait-Fischer E, Rüschenbaum S, Thomas D, Snodgrass RG, Geisslinger G, Baba HA, Trebicka J, Zeuzem S, Weigert A, Lange CM, Brüne B. Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis. Front Immunol 2020;11:1447. [PMID: 32760397 DOI: 10.3389/fimmu.2020.01447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Börgeson E. The role of lipoxins in cardiometabolic physiology and disease. Cardiovascular Endocrinology 2016;5:4-13. [DOI: 10.1097/xce.0000000000000068] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Cole SL, Dunning J, Kok WL, Benam KH, Benlahrech A, Repapi E, Martinez FO, Drumright L, Powell TJ, Bennett M, Elderfield R, Thomas C, Dong T, McCauley J, Liew FY, Taylor S, Zambon M, Barclay W, Cerundolo V, Openshaw PJ, McMichael AJ, Ho LP; MOSAIC investigators. M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight 2017;2:e91868. [PMID: 28405622 DOI: 10.1172/jci.insight.91868] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
15 Dai M, Wu L, Wang P, Wen Z, Xu X, Wang DW. CYP2J2 and Its Metabolites EETs Attenuate Insulin Resistance via Regulating Macrophage Polarization in Adipose Tissue. Sci Rep 2017;7:46743. [PMID: 28440284 DOI: 10.1038/srep46743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
16 Lv Z, Shan X, Tu Q, Wang J, Chen J, Yang Y. Ginkgolide B treatment regulated intestinal flora to improve high-fat diet induced atherosclerosis in ApoE−/− mice. Biomedicine & Pharmacotherapy 2021;134:111100. [DOI: 10.1016/j.biopha.2020.111100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Zhang L, Jia M, Sun T. The roles of special proresolving mediators in pain relief. Reviews in the Neurosciences 2018;29:645-60. [DOI: 10.1515/revneuro-2017-0074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, Gray SP, Pickering R, Tan SM, Ali-Shah ST, Guiry PJ, El-Osta A, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P. Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. J Am Soc Nephrol 2018;29:1437-48. [PMID: 29490938 DOI: 10.1681/ASN.2017101112] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
19 Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases. Int J Mol Sci 2018;19:E3285. [PMID: 30360467 DOI: 10.3390/ijms19113285] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 19.5] [Reference Citation Analysis]
20 Goicoechea M, Sanchez-niño MD, Ortiz A, García de Vinuesa S, Quiroga B, Bernis C, Morales E, Fernández-juarez G, de Sequera P, Verdalles U, Verde E, Luño J. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 2017;125:8-13. [DOI: 10.1016/j.plefa.2017.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
21 Szczuko M, Palma J, Kikut J, Komorniak N, Ziętek M. Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology. Inflamm Res 2020;69:869-81. [PMID: 32488315 DOI: 10.1007/s00011-020-01358-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Gao H, Zhao L, Wang H, Xie E, Wang X, Wu Q, Yu Y, He X, Ji H, Rink L, Min J, Wang F. Metal transporter Slc39a10 regulates susceptibility to inflammatory stimuli by controlling macrophage survival. Proc Natl Acad Sci U S A 2017;114:12940-5. [PMID: 29180421 DOI: 10.1073/pnas.1708018114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
23 Okada K, Hosooka T, Shinohara M, Ogawa W. Modulation of lipid mediator profile may contribute to amelioration of chronic inflammation in adipose tissue of obese mice by pioglitazone. Biochem Biophys Res Commun 2018;505:29-35. [PMID: 30236987 DOI: 10.1016/j.bbrc.2018.09.081] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Long M, Li X, Li L, Dodson M, Zhang DD, Zheng H. Multifunctional p62 Effects Underlie Diverse Metabolic Diseases. Trends Endocrinol Metab 2017;28:818-30. [PMID: 28966079 DOI: 10.1016/j.tem.2017.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
25 Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin Investig Drugs 2018;27:917-30. [PMID: 30334635 DOI: 10.1080/13543784.2018.1538352] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
26 Zhang H, Lu J, Liu H, Guan L, Xu S, Wang Z, Qiu Y, Liu H, Peng L, Men X. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. Pharmacol Res 2021;174:105964. [PMID: 34732369 DOI: 10.1016/j.phrs.2021.105964] [Reference Citation Analysis]
27 Yao L, Wang C, Zhang X, Peng L, Liu W, Zhang X, Liu Y, He J, Jiang C, Ai D, Zhu Y. Hyperhomocysteinemia activates the aryl hydrocarbon receptor/CD36 pathway to promote hepatic steatosis in mice. Hepatology 2016;64:92-105. [PMID: 26928949 DOI: 10.1002/hep.28518] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
28 Fu T, Mohan M, Brennan EP, Woodman OL, Godson C, Kantharidis P, Ritchie RH, Qin CX. Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease. ACS Pharmacol Transl Sci 2020;3:43-55. [PMID: 32259087 DOI: 10.1021/acsptsci.9b00097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
29 Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K. AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia 2017;60:729-39. [PMID: 28188334 DOI: 10.1007/s00125-017-4211-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
30 Lee C, Kim J, Han J, Oh D, Kim M, Jeong H, Kim T, Kim S, Kim JN, Seo Y, Suzuki A, Kim JH, Jung Y. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-28138-6] [Reference Citation Analysis]
31 Rius B, Duran‐güell M, Flores‐costa R, López‐vicario C, Lopategi A, Alcaraz‐quiles J, Casulleras M, José Lozano J, Titos E, Clària J. The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia‐induced endoplasmic reticulum stress. FASEB j 2017;31:5384-98. [DOI: 10.1096/fj.201700394r] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
32 Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019; 17: 2776-2784. e4. [PMID: 31077838 DOI: 10.1016/j.cgh.2019.04.061] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
33 Park J, Langmead CJ, Riddy DM. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. ACS Pharmacol Transl Sci 2020;3:88-106. [PMID: 32259091 DOI: 10.1021/acsptsci.9b00075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
34 Perucci LO, Sugimoto MA, Gomes KB, Dusse LM, Teixeira MM, Sousa LP. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. Expert Opin Ther Targets 2017;21:879-96. [PMID: 28786708 DOI: 10.1080/14728222.2017.1364363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
35 Halenova T, Savchuk O, Ostapchenko L, Chursov A, Fridlyand N, Komissarov AB, Venanzi F, Kolesnikov SI, Sufianov AA, Sherman MY, Gabai VL, Shneider AM. P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions. Oncotarget 2017;8:56030-40. [PMID: 28915571 DOI: 10.18632/oncotarget.19840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
36 Guimarães RC, Gonçalves TT, Leiria LO. Exploiting oxidized lipids and the lipid-binding GPCRs against cardiometabolic diseases. Br J Pharmacol 2021;178:531-49. [PMID: 33169375 DOI: 10.1111/bph.15321] [Reference Citation Analysis]
37 Chen J, Zeng W, Pan W, Peng C, Zhang J, Su J, Long W, Zhao H, Zuo X, Xie X, Wu J, Nie L, Zhao HY, Wei HJ, Chen X. Symptoms of systemic lupus erythematosus are diagnosed in leptin transgenic pigs. PLoS Biol 2018;16:e2005354. [PMID: 30169503 DOI: 10.1371/journal.pbio.2005354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Laiglesia LM, Lorente-cebrián S, Martínez-fernández L, Sáinz N, Prieto-hontoria PL, Burrell MA, Rodríguez-ortigosa CM, Martínez JA, Moreno-aliaga MJ. Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice. Int J Obes 2018;42:572-9. [DOI: 10.1038/ijo.2017.226] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
39 Galvão I, Melo EM, de Oliveira VLS, Vago JP, Queiroz-Junior C, de Gaetano M, Brennan E, Gahan K, Guiry PJ, Godson C, Teixeira MM. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. Pharmacol Res 2021;165:105445. [PMID: 33493655 DOI: 10.1016/j.phrs.2021.105445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Clària J, López-vicario C, Rius B, Titos E. Pro-resolving actions of SPM in adipose tissue biology. Molecular Aspects of Medicine 2017;58:83-92. [DOI: 10.1016/j.mam.2017.03.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
41 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
42 Lin L, Luo X, Wang L, Xu F, He Y, Wang Q, Yuan C, Xu J, Yan L, Hao H. BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway. Int Immunopharmacol 2020;85:106625. [PMID: 32485356 DOI: 10.1016/j.intimp.2020.106625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Wu SH, Chen XQ, Lü J, Wang MJ. BML-111 Attenuates Renal Ischemia/Reperfusion Injury Via Peroxisome Proliferator-Activated Receptor-α-Regulated Heme Oxygenase-1. Inflammation 2016;39:611-24. [PMID: 26597893 DOI: 10.1007/s10753-015-0286-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
44 Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20:12. [PMID: 29480368 DOI: 10.1007/s11906-018-0812-z] [Cited by in Crossref: 663] [Cited by in F6Publishing: 592] [Article Influence: 165.8] [Reference Citation Analysis]
45 Ávila-Román J, Talero E, Rodríguez-Luna A, García-Mauriño S, Motilva V. Anti-inflammatory effects of an oxylipin-containing lyophilised biomass from a microalga in a murine recurrent colitis model. Br J Nutr 2016;116:2044-52. [PMID: 28025954 DOI: 10.1017/S0007114516004189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
46 Wang T, Fu X, Chen Q, Patra JK, Wang D, Wang Z, Gai Z. Arachidonic Acid Metabolism and Kidney Inflammation. Int J Mol Sci 2019;20:E3683. [PMID: 31357612 DOI: 10.3390/ijms20153683] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
47 Kraft JD, Blomgran R, Bergström I, Soták M, Clark M, Rani A, Rajan MR, Dalli J, Nyström S, Quiding‐järbrink M, Bromberg J, Skoog P, Börgeson E. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis. The FASEB Journal 2022;36. [DOI: 10.1096/fj.202101219rr] [Reference Citation Analysis]
48 Curley S, Gall J, Byrne R, Yvan‐charvet L, Mcgillicuddy FC. Metabolic Inflammation in Obesity—At the Crossroads between Fatty Acid and Cholesterol Metabolism. Mol Nutr Food Res 2021;65:1900482. [DOI: 10.1002/mnfr.201900482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Doyle R, Godson C, Brennan E. Promoting resolution in kidney disease: are we nearly there yet? Curr Opin Nephrol Hypertens 2020;29:119-27. [PMID: 31599748 DOI: 10.1097/MNH.0000000000000558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Vartak T, Godson C, Brennan E. Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv Drug Deliv Rev 2021;178:113965. [PMID: 34508793 DOI: 10.1016/j.addr.2021.113965] [Reference Citation Analysis]
51 Kraft JD, Blomgran R, Lundgaard I, Quiding-Järbrink M, Bromberg JS, Börgeson E. Specialized Pro-Resolving Mediators and the Lymphatic System. Int J Mol Sci 2021;22:2750. [PMID: 33803130 DOI: 10.3390/ijms22052750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Gila-Diaz A, Carrillo GH, Singh P, Ramiro-Cortijo D. Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases. Antioxidants (Basel) 2021;10:933. [PMID: 34201378 DOI: 10.3390/antiox10060933] [Reference Citation Analysis]
53 Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14:105-120. [PMID: 29199276 DOI: 10.1038/nrneph.2017.157] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
54 Brennan E, Mohan M, Andrews D, Bose M, Kantharidis P. Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science 2019;133:2121-41. [DOI: 10.1042/cs20190067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
55 Bukosza EN, Kaucsár T, Godó M, Lajtár E, Tod P, Koncsos G, Varga ZV, Baranyai T, Nguyen MT, Schachner H, Sőti C, Ferdinandy P, Giricz Z, Szénási G, Hamar P. Glomerular Collagen Deposition and Lipocalin-2 Expression Are Early Signs of Renal Injury in Prediabetic Obese Rats. Int J Mol Sci 2019;20:E4266. [PMID: 31480394 DOI: 10.3390/ijms20174266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
56 Hasturk H, Schulte F, Martins M, Sherzai H, Floros C, Cugini M, Chiu CJ, Hardt M, Van Dyke T. Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation. Front Immunol 2021;12:704163. [PMID: 34589083 DOI: 10.3389/fimmu.2021.704163] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Perretti M, Godson C. Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology. Br J Pharmacol 2020;177:4595-600. [PMID: 32954491 DOI: 10.1111/bph.15212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
58 Wu S, Pan L, Liao H, Yao W, Shen N, Chen C, Liu D, Ge M. High-fat diet increased NADPH-oxidase-related oxidative stress and aggravated LPS-induced intestine injury. Life Sci 2020;253:117539. [PMID: 32165213 DOI: 10.1016/j.lfs.2020.117539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
59 Al-Shaer AE, Buddenbaum N, Shaikh SR. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158936. [PMID: 33794384 DOI: 10.1016/j.bbalip.2021.158936] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol 2017;187:1211-21. [PMID: 28527709 DOI: 10.1016/j.ajpath.2017.01.018] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 17.4] [Reference Citation Analysis]
61 Habouri L, El Mansouri FE, Ouhaddi Y, Lussier B, Pelletier JP, Martel-Pelletier J, Benderdour M, Fahmi H. Deletion of 12/15-lipoxygenase accelerates the development of aging-associated and instability-induced osteoarthritis. Osteoarthritis Cartilage 2017;25:1719-28. [PMID: 28694081 DOI: 10.1016/j.joca.2017.07.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
62 Crean D, Godson C. Specialised lipid mediators and their targets. Seminars in Immunology 2015;27:169-76. [DOI: 10.1016/j.smim.2015.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
63 Pabon MA, Ma KC, Choi AM. Autophagy and Obesity-Related Lung Disease. Am J Respir Cell Mol Biol 2016;54:636-46. [PMID: 26900794 DOI: 10.1165/rcmb.2016-0045PS] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
64 Baptista LC, Sun Y, Carter CS, Buford TW. Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty. Front Nutr 2020;7:17. [PMID: 32219095 DOI: 10.3389/fnut.2020.00017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Lee JK, Luchian T, Park Y. Effect of Regular Exercise on Inflammation Induced by Drug-resistant Staphylococcus aureus 3089 in ICR mice. Sci Rep 2015;5:16364. [PMID: 26542343 DOI: 10.1038/srep16364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Han YH, Lee K, Saha A, Han J, Choi H, Noh M, Lee YH, Lee MO. Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders. Biomol Ther (Seoul) 2021;29:455-64. [PMID: 34162770 DOI: 10.4062/biomolther.2021.094] [Reference Citation Analysis]
67 Andrewartha N, Yeoh G. Human Amnion Epithelial Cell Therapy for Chronic Liver Disease. Stem Cells Int 2019;2019:8106482. [PMID: 31485235 DOI: 10.1155/2019/8106482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
68 Yang Y, Wang Y, Kong Y, Zhang X, Zhang H, Gang Y, Bai L. The therapeutic effects of lipoxin A4 during treadmill exercise on monosodium iodoacetate-induced osteoarthritis in rats. Molecular Immunology 2018;103:35-45. [DOI: 10.1016/j.molimm.2018.08.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Kaufmann B, Reca A, Kim AD, Feldstein AE. Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications. Semin Liver Dis 2021;41:150-62. [PMID: 34107544 DOI: 10.1055/s-0041-1723031] [Reference Citation Analysis]
70 Li Y, Wang N, Ma Z, Wang Y, Yuan Y, Zhong Z, Hong Y, Zhao M. Lipoxin A4 protects against paraquat‑induced acute lung injury by inhibiting the TLR4/MyD88‑mediated activation of the NF‑κB and PI3K/AKT pathways. Int J Mol Med 2021;47:86. [PMID: 33760150 DOI: 10.3892/ijmm.2021.4919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Yoshino K, Hosooka T, Shinohara M, Aoki C, Hosokawa Y, Imamori M, Ogawa W. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. Biochem Biophys Res Commun 2021;557:62-8. [PMID: 33862461 DOI: 10.1016/j.bbrc.2021.04.012] [Reference Citation Analysis]
72 Musso G, Gambino R, Cassader M, Paschetta E, Sircana A. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. Trends in Pharmacological Sciences 2018;39:387-401. [DOI: 10.1016/j.tips.2018.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
73 Park YS, Uddin MJ, Piao L, Hwang I, Lee JH, Ha H. Novel Role of Endogenous Catalase in Macrophage Polarization in Adipose Tissue. Mediators Inflamm 2016;2016:8675905. [PMID: 27597806 DOI: 10.1155/2016/8675905] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
74 Chen Y, Zheng Y, Xin L, Zhong S, Liu A, Lai W, Liu L, Lin C, Liao C, Zeng J, Zhang L. 15-epi-lipoxin A4 inhibits TNF-α-induced tissue factor expression via the PI3K/AKT/ NF-κB axis in human umbilical vein endothelial cells. Biomedicine & Pharmacotherapy 2019;117:109099. [DOI: 10.1016/j.biopha.2019.109099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Eur J Med Chem 2021;213:113167. [PMID: 33486199 DOI: 10.1016/j.ejmech.2021.113167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
76 Wang C, Chen J, Wang P, Qing S, Li W, Lu J. Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis. Front Endocrinol 2022;13:821028. [DOI: 10.3389/fendo.2022.821028] [Reference Citation Analysis]
77 Hughes MF, Lenighan YM, Godson C, Roche HM. Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism. Front Cardiovasc Med 2018;5:148. [PMID: 30460244 DOI: 10.3389/fcvm.2018.00148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Fiala M, Kooij G, Wagner K, Hammock B, Pellegrini M. Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids. FASEB J 2017;31:3229-39. [PMID: 28420693 DOI: 10.1096/fj.201700065R] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
79 Gundala NKV, Naidu VGM, Das UN. Arachidonic acid and lipoxinA4 attenuate streptozotocin-induced cytotoxicity to RIN5 F cells in vitro and type 1 and type 2 diabetes mellitus in vivo. Nutrition 2017;35:61-80. [PMID: 28241993 DOI: 10.1016/j.nut.2016.10.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
80 Declèves AE, Mathew AV, Armando AM, Han X, Dennis EA, Quehenberger O, Sharma K. AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice. J Lipid Res 2019;60:937-52. [PMID: 30862696 DOI: 10.1194/jlr.M088690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
81 Guo YP, Jiang HK, Jiang H, Tian HY, Li L. Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-κB and ERK/p38 MAPK-dependent inflammation. Life Sci 2018;198:112-8. [PMID: 29499280 DOI: 10.1016/j.lfs.2018.02.039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
82 Li Z, Wu W, Yang L, Gu L, Zhao T, Tang T, Zhou X, Qin G. No elevation of serum adiponectin in OSA patients after continuous positive airway pressure treatment: a meta-analysis. Sleep Biol Rhythms 2016;14:287-93. [DOI: 10.1007/s41105-016-0057-7] [Reference Citation Analysis]
83 Gromovsky AD, Schugar RC, Brown AL, Helsley RN, Burrows AC, Ferguson D, Zhang R, Sansbury BE, Lee RG, Morton RE, Allende DS, Parks JS, Spite M, Brown JM. Δ-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 2018;38:218-31. [PMID: 29074585 DOI: 10.1161/ATVBAHA.117.309660] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 9.2] [Reference Citation Analysis]
84 Crouch M, Al-Shaer A, Shaikh SR. Hormonal Dysregulation and Unbalanced Specialized Pro-Resolving Mediator Biosynthesis Contribute toward Impaired B Cell Outcomes in Obesity. Mol Nutr Food Res 2021;65:e1900924. [PMID: 32112513 DOI: 10.1002/mnfr.201900924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
85 Musso G, Cassader M, Paschetta E, Gambino R. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155:282-302.e8. [PMID: 29906416 DOI: 10.1053/j.gastro.2018.06.031] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 24.0] [Reference Citation Analysis]
86 Liu H, Zhou K, Liao L, Zhang T, Yang M, Sun C. Lipoxin A4 receptor agonist BML-111 induces autophagy in alveolar macrophages and protects from acute lung injury by activating MAPK signaling. Respir Res 2018;19:243. [PMID: 30518355 DOI: 10.1186/s12931-018-0937-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
87 Kayser BD, Lhomme M, Prifti E, Da Cunha C, Marquet F, Chain F, Naas I, Pelloux V, Dao MC, Kontush A, Rizkalla SW, Aron-Wisnewsky J, Bermúdez-Humarán LG, Oakley F, Langella P, Clément K, Dugail I. Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity. FASEB J 2019;33:4741-54. [PMID: 30608881 DOI: 10.1096/fj.201801897R] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
88 Flitter BA, Fang X, Matthay MA, Gronert K. The potential of lipid mediator networks as ocular surface therapeutics and biomarkers. Ocul Surf 2021;19:104-14. [PMID: 32360792 DOI: 10.1016/j.jtos.2020.04.008] [Reference Citation Analysis]
89 Martínez-fernández L, Fernández-galilea M, Felix-soriano E, Escoté X, González-muniesa P, Moreno-aliaga MJ. Inflammation and Oxidative Stress in Adipose Tissue. Obesity. Elsevier; 2018. pp. 63-92. [DOI: 10.1016/b978-0-12-812504-5.00004-0] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Yamashita AS, Belchior T, Lira FS, Bishop NC, Wessner B, Rosa JC, Festuccia WT. Regulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors. Mediators Inflamm 2018;2018:8261432. [PMID: 30116154 DOI: 10.1155/2018/8261432] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
91 Suzuki T, Ishii S, Shinohara M, Kawano Y, Wakahashi K, Kawano H, Sada A, Minagawa K, Hamada M, Takahashi S, Furuyashiki T, Tan NS, Matsui T, Katayama Y. Mobilization efficiency is critically regulated by fat via marrow PPARδ. Haematologica 2021;106:1671-83. [PMID: 33538151 DOI: 10.3324/haematol.2020.265751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Martínez-Fernández L, González-Muniesa P, Laiglesia LM, Sáinz N, Prieto-Hontoria PL, Escoté X, Odriozola L, Corrales FJ, Arbones-Mainar JM, Martínez JA, Moreno-Aliaga MJ. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J 2017;31:2135-45. [PMID: 28188173 DOI: 10.1096/fj.201600859R] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
93 Li Q, Ge C, Tan J, Sun Y, Kuang Q, Dai X, Zhong S, Yi C, Hu LF, Lou DS, Xu M. Juglanin protects against high fat diet-induced renal injury by suppressing inflammation and dyslipidemia via regulating NF-κB/HDAC3 signaling. Int Immunopharmacol 2021;95:107340. [PMID: 33667999 DOI: 10.1016/j.intimp.2020.107340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 DeVito LM, Dennis EA, Kahn BB, Shulman GI, Witztum JL, Sadhu S, Nickels J, Spite M, Smyth S, Spiegel S. Bioactive lipids and metabolic syndrome-a symposium report. Ann N Y Acad Sci 2022. [PMID: 35218041 DOI: 10.1111/nyas.14752] [Reference Citation Analysis]
95 Recchiuti A, Isopi E, Romano M, Mattoscio D. Roles of Specialized Pro-Resolving Lipid Mediators in Autophagy and Inflammation. Int J Mol Sci 2020;21:E6637. [PMID: 32927853 DOI: 10.3390/ijms21186637] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Brennan E, Kantharidis P, Cooper ME, Godson C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol 2021. [PMID: 34282342 DOI: 10.1038/s41581-021-00454-y] [Reference Citation Analysis]
97 Huang R, Ding X, Fu H, Cai Q. Potential mechanisms of sleeve gastrectomy for reducing weight and improving metabolism in patients with obesity. Surgery for Obesity and Related Diseases 2019;15:1861-71. [DOI: 10.1016/j.soard.2019.06.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
98 Andrews D, Godson C. Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158940. [PMID: 33839296 DOI: 10.1016/j.bbalip.2021.158940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Li Y, Wang L, Xu B, Zhao L, Li L, Xu K, Tang A, Zhou S, Song L, Zhang X, Zhan H. Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps sinensis on the Treatment of Diabetic Nephropathy. J Diabetes Res 2021;2021:8891093. [PMID: 33628839 DOI: 10.1155/2021/8891093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Chen X, Zhuo S, Zhu T, Yao P, Yang M, Mei H, Li N, Ma F, Wang JM, Chen S, Ye RD, Li Y, Le Y. Fpr2 Deficiency Alleviates Diet-Induced Insulin Resistance Through Reducing Body Weight Gain and Inhibiting Inflammation Mediated by Macrophage Chemotaxis and M1 Polarization. Diabetes 2019;68:1130-42. [PMID: 30862681 DOI: 10.2337/db18-0469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
101 Pietrani NT, Ferreira CN, Rodrigues KF, Perucci LO, Carneiro FS, Bosco AA, Oliveira MC, Pereira SS, Teixeira AL, Alvarez-Leite JI, Ferreira AV, Sousa LP, Gomes KB. Proresolving protein Annexin A1: The role in type 2 diabetes mellitus and obesity. Biomed Pharmacother 2018;103:482-9. [PMID: 29677533 DOI: 10.1016/j.biopha.2018.04.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
102 Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. 2017;17:248-261. [PMID: 28287106 DOI: 10.1038/nri.2017.10] [Cited by in Crossref: 215] [Cited by in F6Publishing: 206] [Article Influence: 43.0] [Reference Citation Analysis]
103 Lu J, Liu Z, Shu M, Zhang L, Xia W, Tang L, Li J, Huang B, Li H. Human placental mesenchymal stem cells ameliorate chemotherapy-induced damage in the testis by reducing apoptosis/oxidative stress and promoting autophagy. Stem Cell Res Ther 2021;12:199. [PMID: 33743823 DOI: 10.1186/s13287-021-02275-z] [Reference Citation Analysis]
104 Bernal L, Alvarado-Vázquez A, Ferreira DW, Paige CA, Ulecia-Morón C, Hill B, Caesar M, Romero-Sandoval EA. Evaluation of a nanotechnology-based approach to induce gene-expression in human THP-1 macrophages under inflammatory conditions. Immunobiology 2017;222:399-408. [PMID: 27615510 DOI: 10.1016/j.imbio.2016.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
105 Brennan EP, Cacace A, Godson C. Specialized pro-resolving mediators in renal fibrosis. Mol Aspects Med 2017;58:102-13. [PMID: 28479307 DOI: 10.1016/j.mam.2017.05.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
106 Clària J, Flores-Costa R, Duran-Güell M, López-Vicario C. Proresolving lipid mediators and liver disease. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:159023. [PMID: 34352389 DOI: 10.1016/j.bbalip.2021.159023] [Reference Citation Analysis]
107 Livne-Bar I, Wei J, Liu HH, Alqawlaq S, Won GJ, Tuccitto A, Gronert K, Flanagan JG, Sivak JM. Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury. J Clin Invest 2017;127:4403-14. [PMID: 29106385 DOI: 10.1172/JCI77398] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
108 Carmona-Hidalgo B, González-Mariscal I, García-Martín A, Prados ME, Ruiz-Pino F, Appendino G, Tena-Sempere M, Muñoz E. Δ9-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in mice. Phytomedicine 2021;81:153426. [PMID: 33341026 DOI: 10.1016/j.phymed.2020.153426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Chen L, Liu H, Wang Y, Xia H, Gong J, Li B, Yao S, Shang Y. Maresin 1 Maintains the Permeability of Lung Epithelial Cells In Vitro and In Vivo. Inflammation 2016;39:1981-9. [PMID: 27613620 DOI: 10.1007/s10753-016-0433-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
110 Connaughton RM, Mcmorrow AM, Mcgillicuddy FC, Lithander FE, Roche HM. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood. Proc Nutr Soc 2016;75:115-24. [DOI: 10.1017/s0029665116000070] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
111 Wang Q, Jin F, Zhang J, Li Z, Yu D. Lipoxin A4 promotes adipogenic differentiation and browning of mouse embryonic fibroblasts. In Vitro Cell Dev Biol Anim 2021;57:953-61. [PMID: 34811702 DOI: 10.1007/s11626-021-00617-y] [Reference Citation Analysis]
112 Leite-Almeida L, Morato M, Cosme D, Afonso J, Areias JC, Guerra A, Caldas Afonso A, Albino-Teixeira A, Sousa T, Correia-Costa L. Impact of physical activity on redox status and nitric oxide bioavailability in nonoverweight and overweight/obese prepubertal children. Free Radic Biol Med 2021;163:116-24. [PMID: 33309779 DOI: 10.1016/j.freeradbiomed.2020.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 de Gaetano M, McEvoy C, Andrews D, Cacace A, Hunter J, Brennan E, Godson C. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Front Pharmacol 2018;9:1488. [PMID: 30618774 DOI: 10.3389/fphar.2018.01488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]